Not known Factual Statements About phenobarbital sodium drug class
Not known Factual Statements About phenobarbital sodium drug class
Blog Article
Watch Carefully (1)pentobarbital will lower the level or effect of fentanyl intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Intently. Coadministration of fentanyl with CYP3A4 inducers may lead to the lower in fentanyl plasma concentrations, not enough efficacy or, quite possibly, growth of the withdrawal syndrome inside of a individual who may have produced Bodily dependence to fentanyl. After stopping a CYP3A4 inducer, since the effects on the inducer drop, the fentanyl plasma concentration will increase which could boost or lengthen each the therapeutic and adverse effects.
pentobarbital will decrease the level or effect of vinorelbine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Unknown.
Contraindicated (1)pentobarbital will lessen the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is actually a delicate CYP3A4 substrate. Coadministration with powerful or average CYP3A4 inducers is contraindicated.
pentobarbital will lower the extent or effect of fentanyl transmucosal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Carefully. Coadministration of fentanyl with CYP3A4 inducers could lead to a lessen in fentanyl plasma concentrations, insufficient efficacy or, possibly, improvement of the withdrawal syndrome in a very client that has formulated Bodily dependence to fentanyl.
pentobarbital will minimize the extent or effect of buprenorphine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
pentobarbital will lessen the extent or effect of repaglinide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will minimize the level or effect of alosetron by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Mysterious.
pentobarbital will decrease the extent or effect of methylprednisolone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
Labor and shipping: Hypnotic doses of these barbiturates do not surface to appreciably impair uterine action for the duration of labor. Entire anesthetic doses of barbiturates decrease the pressure and frequency of uterine contractions. Administration of sedative-hypnotic barbiturates towards the mother through labor may possibly lead to respiratory despair within the new phenobarbital sodium acid or base child. Untimely infants are especially at risk of the depressant effects of barbiturates.
pentobarbital will decrease the level or effect of vincristine liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Not known.
Contraindicated (1)pentobarbital will lower the extent or effect of lorlatinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will reduce the level or effect of estrogens esterified by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will decrease the level or effect of bosentan by impacting hepatic enzyme CYP2C9/10 metabolism. Small/Importance Mysterious.
Anticoagulants: Phenobarbital lowers the plasma levels of dicumarol (name Earlier used: bishydroxycoumarin) and causes a reduce in anticoagulant exercise as measured because of the prothrombin time. Barbiturates can induce hepatic microsomal enzymes resulting in amplified metabolism and diminished anticoagulant reaction of oral anticoagulants (e.